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Abstract
Background: The prevalence of thyroid nodules increases with age, average 4–7% for the U.S.A. adult population, but it is
much higher (19–67%) when sub-clinical nodules are considered. About 90% of these lesions are benign and a reliable
approach to their preoperative characterization is necessary. Unfortunately conventional thyroid scintigraphy does not
allow the distinction among benign and malignant thyroid proliferations but it provides only functional information (cold or
hot nodules). The expression of the anti-apoptotic molecule galectin-3 is restricted to cancer cells and this feature has
potential diagnostic and therapeutic implications. We show here the possibility to obtain thyroid cancer imaging in vivo by
targeting galectin-3.
Methods: The galectin-3 based thyroid immuno-scintigraphy uses as radiotracer a specific
99mTc-radiolabeled mAb. A
position-sensitive high-resolution mini-gamma camera was used as imaging capture device. Human galectin-3 positive
thyroid cancer xenografts (ARO) and galectin-3 knockout tumors were used as targets in different experiments in vivo.3 8
mice with tumor mass of about 1 gm were injected in the tail vein with 100 mCi of
99mTc-labeled mAb to galectin-3 (30 mg
protein/in 100 ml saline solution). Tumor images were acquired at 1 hr, 3 hrs, 6 hrs, 9 hrs and 24 hrs post injection by using
the mini-gamma camera.
Findings: Results from different consecutive experiments show an optimal visualization of thyroid cancer xenografts
between 6 and 9 hours from injection of the radiotracer. Galectin-3 negative tumors were not detected at all. At 6 hrs post-
injection galectin-3 expressing tumors were correctly visualized, while the whole-body activity had essentially cleared.
Conclusions: These results demonstrate the possibility to distinguish preoperatively benign from malignant thyroid nodules
by using a specific galectin-3 radio-immunotargeting. In vivo imaging of thyroid cancer may allow a better selection of
patients referred to surgery. The possibility to apply this method for imaging and treatment of other galectin-3 expressing
tumors is also discussed.
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Introduction
The high prevalence of benign thyroid nodules in adult
population makes the preoperative detection of thyroid cancer
comparable to ‘looking for a needle in a haystack’. The prevalence
of thyroid nodules increases with age, average 4–7% for the
U.S.A. adult population [1] but it is much higher (19–67%) when
sub-clinical nodules are also considered [2]. Fortunately, about
90% of these lesions are benign and for this reason a reliable and
systematic approach to their preoperative characterization is
necessary [1,3].
The expression of Sodium Iodide Symporter (NIS) on the
membrane of the thyroid cells allows the thyroid gland to
concentrate iodide from the serum. NIS-mediated iodide uptake
is required for the subsequent organification and oxidation steps,
which are key events for the production of thyroid hormones. This
peculiar property of the gland supports conventional thyroid
scintigraphy, which uses radioiodine in defining the thyroid gland
in both physiological and pathological states [4]. However this
widely used technique does not allow the distinction among benign
and malignant thyroid proliferations. In fact although cancer is
unusual in thyroid nodules with efficient iodide uptake (worded hot
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concentrate iodide (cold nodules) are biologically benign [4].
Normally thyroid cells do not express galectin-3. A forced
expression of galectin-3 via specific cDNA transfection generates a
transformed phenotype, blocking the apoptotic program, a feature
that favors the development of cancer [5–9]. Interestingly, as
previously reported in a large multicentre retrospective study on
histological material, well-differentiated thyroid carcinomas almost
invariably express galectin-3 (.94% of all thyroid cancer types,
with exclusion of the medullary carcinoma), while benign thyroid
proliferations do not (only 2% of the benign nodules, mostly
represented by adenomas, were galectin-3 positive) [10]. This
finding was confirmed by several studies reported in the literature
[11–14] and galectin-3 immunostaining is already used in the
clinical practice, at immuno-cytological level, for a better selection
of patients referred to thyroidectomy [10,15–17]. In this study, by
using in vivo and ex vivo experimental models of thyroid cancer we
show the possibility to obtain a reliable thyroid cancer imaging in
vivo by targeting the galectin-3 lectin molecule. This diagnostic
approach may be also used for imaging different galectin-3
expressing tumors in vivo.
Materials and Methods
Cell lines and galectin-3 mRNA interference
Thyroid carcinoma cell lines ARO, kindly provided by Dr.
Silvia Soddu (National Cancer Institute Regina Elena of Rome,
Italy) was previously described [18–19]. Although the thyroid
origin of ARO cells has been recently questioned [20], this
galectin-3 positive cell line grows very efficiently in vivo and
provides an useful model for setting experiments of galectin-3
immunotargeting with and without galectin-3 mRNA interference.
Cells were cultured in standard conditions at 37uC and 5% CO2
atmosphere in RPMI-1640 medium supplemented with 2 mM
glutamine, 10% FCS, penicillin and streptomycin (GIBCO BRL,
Gaithersburg, MD).
For galectin-3 mRNAinterference three different sequences were
identified and tested as reported previously [21]. The two following
sequences, which strongly and similarly down regulated galectin-3
expression in ARO cells were sub-cloned into pSUPER vector and







39 (Gal3-845, sense); and 59-AGCTTTTCCAAAAAACCTTAC-
ATGTG TAAAGGTTCTCTTGAAACCTTTACACATGTA-
AGGTGGG-39 (gal3-845, antisense).
In the experiment shown in Figure 1 (panel B) ARO cells were
stably transfected with pSUPER-Gal3-551 (ARO-Gal-3i) vector
and mock transfected with pSUPER vector as control (ARO-ctr).
Selection of stably transfected cells was performed by treatment
with puromycin 2 mg/ml (Sigma) 72 hrs after transfection.
Down-regulation of Galectin-3 expression was checked in
western blot analysis at different time points (12–72 hrs after
transfection and tumour cells injection in mice).
Monoclonal antibodies and immunohistochemistry
A purified horseradish-peroxidase conjugated (HRP-conjugat-
ed) rat monoclonal antibody to galectin-3 (SPACE s.r.l., Milan,
Italy) was used in immunohisto-cytochemistry according to the
manufacturer’s instructions as previously reported [13]. Briefly,
antigen-retrieval microwave treatment of tissues slides in
0.01 mol/L citrate buffer pH 6.0 was applied for three cycles of
3 minutes each at 750 W. Purified rat mAb directed to galectin-3
was used at a concentration range of 5–10 mg/ml. The enzymatic
activity was visualized with 3, 39-diamino-benzidine (Dako,
Glostrup, Denmark).
Western Blot analysis
Total cell extracts (TCEs) were obtained using a lysis buffer
composed by: Tris HCl 50 mM, NaCl 150 mM, Tween 20 1%,
PMSF 1 mM and 1 tablet of complete protein inhibitor cocktail
(Roche). An aliquot of TCE (30–70 mg) was separated in 10%
SDS-PAGE, then blotted onto nitrocellulose membrane (BIO-
RAD). The following antibodies were used in immunoblotting: a
purified rat mAb to galectin-3 (Mabtech AB, Nacka Strand,
Sweden), a mouse mAb anti-a-tubulin (TU-02, Santa Cruz
Biotechnology) and HRP-conjugated anti-mouse IgG and anti-
rat IgG specific antisera (Sigma). Immunoreactivity was detected
by using chemo-luminescence analysis (ECL kit, Amersham
Corporation). The molecular species resolved in western blotting
were finally analyzed by densitometry, using a dedicate software
(NIH ImageJ, version 1.32j).
Results are expressed as relative densitometry unit (rdu) after
normalization with densitometry values of the band obtained for
a-tubulin.
Murine models of thyroid cancer xenografts
Pathogen-free 4–5-week-old nude (nu/nu) mice (Charles River,
USA) were used for establishing thyroid cancer xenografts in vivo.
Mice were kept in cages of 4 animals each with water and food ad
libitum. Galectin-3 expressing and highly tumorigenic poorly
differentiated follicular thyroid carcinoma cell line (ARO) and
the derived galectin-3 knockout ARO cells (ARO-Gal3 negative)
were considered for these experiments.
Wild-type and interfered ARO cells were maintained in
standard culture conditions as aforementioned, detached from
tissue culture plates with trypsin 0,05%-EDTA 0,02% (Gibco),
washed in sterile PBS and injected subcutaneously into nude mice
at a concentration ranging from 7610
6 to 10
7 cells /0.2 ml saline
solution, depending by the experiment. Injection of the cells was
performed by using a standard insulin needle.
No anesthesia was necessary. Fifty animals were used in three
different sets of experiments for establishing tumor xenografs.
Mice were examined three times a week for signs of measurable
tumor growth.
Mice were selected for in vivo imaging experiments when tumor
weight was around 0.5–1 gm. To determine the in vivo expression
of galectin-3 in tumor xenografts, some of the tumors were
surgically excised and used for galectin-3 expression analysis as
reported above. This work was performed according to the specific
guidelines provided by the Italian Ministry of Public Health for the
animal experimentation. This study has been approved by the
Institutional Ethical Committee for animal experimentation at the
National Cancer Institute Regina Elena of Rome. The animal
facility at the NCI of Rome is certified by the Italian Ministry of
Public Health.
Radio labeling of monoclonal antibody to Galectin-3
Affinity purified and highly concentrated (5 mg/ml) monoclonal
antibody to human Galectin-3 (Mabtech, Nacka, Sweden) was
radio labeled by using the method previously reported [22].
Briefly, antibody disulfide bridges were reduced using a molar
excess of 2-mercaptoethanol (Sigma-Aldrich) for 30 minutes at
room temperature followed by purification with a Sephadex G-25
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cold phosphate buffer pH 7.4 as eluant. The reduced antibody
was stored at 280uC until use. Activated galectin-3 mAb (400 mg
/200 ml volume) was labeled by adding 7 ml of a methylen-
diposphonate (MDP) bone scan kit (MedrotecH, Amersham
Health, UK) as previously reported [22] and 10 mCi (370 MBq)
of
99mTcO4
2 freshly eluted from (
99Mo/
99mTc) generator (GE-
Healthcare, UK). Labeling efficiency (LE) was assessed by using
Instant Thin Layer Chromatography (ITLC-SG, VWR, Italy)
with 0.9% NaCl as mobile phase.
The strips were analyzed by a computerized mini-radio scanner
(Bioscan System, Italy). LE, was .95% with a final specific activity
of 70 mCi/mg( Fig. S1 online).
In order to optimize the efficiency of antibody labeling several
experiments were performed varying the molar ratio 2-mercap-
toethanol/mAb (range: 1.000:1 to 4.000:1) and the ratio mAb /
99mTc for labeling (range 250.000:1 to 4.500.000:1).
The reduction of disulfide bridges at a molar ratio of 2145:1 (2-
mercaptoethanol /mAb) and a molar ratio of 1,500,000:1 for
Ab/
99mTc gave the highest LE of
99mTc-anti-Galectin-3 and were
used for all further experiments (Fig. S1 online).
Specific stability studies were performed incubating fresh radio
labeled antibody in saline or human plasma at 37u C for 24 hrs
and evaluating the radiopharmaceutical purity by ITLC-SG at
different time points (1 hr, 3 hrs, 6 hrs and 24 hrs). The stability in
saline and plasma was high during the first 6 hours (.90% and
.80% for saline and plasma, respectively) with a slight decrease at
24 h (Fig. S1 online).
High Resolution Gamma Camera
The High Resolution gamma Camera (HRC) (Li-tech S.r.l.,
Italy), shown in figure S2 online is composed by a crystal-
collimator structure coupled to a Hamamatsu H8500 (Hama-
Figure 1. In vivo detection of galectin-3 positive ARO xenografts by using radio immunoscintigraphy with
99mTc-labeled mAb to
galectin-3. A) Image acquired with a high-resolution mini gamma camera in a mouse bearing ARO (Gal3+) xenograft after 6 hrs from i.v. injection of
100 mCi of
99mTc-labelled mAb to Galectin-3. The arrow shows the tumor mass revealed in the left leg. A consistent accumulation of the radio tracer is
observed in the liver according to the clearance of exogenous mAb (panel 1A); Morphological and immunohistochemical evaluation of the excised
tumor xenograft show a poorly differentiated thyroid cancer with a variable expression of galectin-3, as revealed by a galectin-3 specific mAb and a
direct immunoperoxidase staining method (panel 2A); The table shows the kinetic of tumor /normal muscle ratio of the radio tracer at different time
points (panel 3A). B) Image acquired with a high-resolution mini gamma camera in a mouse bearing Galectin-3 interfered ARO xenograft (Gal32)
after 6 hrs from i.v. injection of 100 mCi of
99mTc-labelled mAb to Galectin-3 (panel 1B); Immunohistochemical evaluation of the excised tumor shows
a consistent down-regulation of galectin-3 expression (panel 2B); The efficiency of stable galectin-3 RNA interference in down regulating galectin-3
expression is demonstrated in immunoblotting. ARO cells mock-transfected with pSUPER vector were used as control (Ctr); galectin-3 interfered ARO
cells were stable transfected with pSUPER-Gal3-551 vector (Gal3i); a-tubulin was used as a loading control. The densitometry analysis of the molecular
species visualized in the gel is also shown (panel 3B). Results are expressed as relative densitometry units (rdu), measured normalizing Gal-3 signal
with the corresponding a-tubulin band intensity.
doi:10.1371/journal.pone.0003768.g001
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charge readout electronics and a data acquisition system.
The patented parallel hole collimator, already described [24–
25] is made of pure Tungsten with 200 mm thick septa. It consists
of a 24 mm collimator arranged over an adjunctive 6 mm
collimator structure, in which crystals are integrated into the
holes. The scintillation structure is composed by 20620 CsI (Tl)
crystals array (Spectra Physics-Hilger, UK) with a Field Of View
(FOV) of 49.0649.0 mm
2. The crystal dimensions are
2.0562.0565.0 mm
3 and each crystal is covered by100 mm white
reflective epoxy on his five blind surfaces. The crystal-collimator
structure is coupled to the PSPMT via optical grease.
The H8500 PSPMT has an external size of 52.0652.0618.0 mm
3
with an active area of 49.0649.0 mm
2. The photocathode is bi-alkali
and the multiplication system, composed by 12 metal channel
dynodes, provides a gain of 3610
6 @ 21000 V.
The multiplied charge is collected by an array of 868 anodes.
The read-out is a miniaturized (52.0652.065.0 mm
3) front-end
electronics, and the signals are sampled with a dedicated compact
USB ADC board. The acquisition system provides 4 channels at
20 M Samples/sec. Data acquisition and processing is performed
on a Linux Embedded System equipped with ARM CPU PXA255
with 100 touch screen. The system control and data processing
software are proprietary applications developed in C++ language.
The system allows performing a real-time acquisition with a
refresh time of 0.5 sec. The system is conceived to be a battery
operated portable device; as a consequence the detector head
weights about 2 kg while the overall weight is about 4.5 kg.
The HRC energy resolution is about 20% FWHM @ 140 keV
(
99mTc) over the whole FOV. The sensitivity is 210 cps/MBq and
the uniformity is 65% while it provides 2.2 mm intrinsic spatial
resolution suitable for our imaging experiments in vivo with tumour
xenografted mice, and ex-vivo with surgical specimens derived from
human patients.
Ex-vivo imaging of human thyroid cancer
As a proof of concept for imaging differentiated thyroid cancer
in human, we performed ex-vivo binding studies using as target a
fresh metastatic cervical lymph node excised from a patient
bearing a papillary thyroid carcinoma. Immediately after surgical
removal the lymph node was cut in half longitudinally through the
cancer lesion and the two tissue sections were incubated at 37u C
for 3 h in a 50 ml solution containing 2 mCi of
99mTc-anti-Gal-3
(0.1 mg protein) in saline solution with 1% HSA in presence or
absence of 100 mg of unlabelled anti-Gal-3 antibody
Results
In order to evaluate the binding specificity of a
99mTc-labeled
mAb to galectin-3 in vivo, six animals bearing galectin-3 positive
carcinoma xenografts (ARO-Gal-3
+) were considered in a
preliminary experiment.
Mice with tumor mass of about 1 gm were injected in the tail
vein (i.v.) with 100 mCi of
99mTc-labeled mAb to galectin-3 (30 mg
protein/in 100 ml saline solution). Images were acquired at 1 hr,
3 hrs, 6 hrs, 9 hrs and 24 hrs post-injection by using the mini-
gamma camera. Galectin-3 immunotargeting of ARO tumors was
highly efficient in xenografted mice. A central area of tumor
necrosis (histologically confirmed) with impaired binding of the
radiotracer was correctly depicted in one of the instances (fig. S2
online). Preliminary experiments with different galectin-3 positive
tumors including melanomas, lymphoma and breast carcinomas
were also considered for this purpose with overlapping results (data
not shown). As expected, the majority of galectin-3 radio labeled
antibody was concentrated in the liver according to the clearance
of exogenous mAbs from the blood [26] (fig. S2 online). In order
to optimize the imaging capture and to demonstrate the binding
specificity of the galectin-3 mAb a larger in vivo experiment
(repeated in triplicate) was considered.
The experiment included 12 xenografted mice, two groups of
six animals each. The first group was transplanted with galectin-3
positive ARO cells at concentration of 5–8610
6 cells/0.2 ml saline
solution/mouse; the second group of mice was transplanted with
galectin-3 knockout ARO cells (ARO-Gal3 negative), obtained by
using a specific galectin-3 RNA interference (iRNA) [20].
ARO-Gal3 negative cells were injected subcutaneously at
concentration of 10
7cells/0.2 ml saline solution/mouse, in order
to promote a rapid tumor growth in vivo in about 4 days.
This was required for maintaining an efficient down-regulation
of galectin-3 expression in stable interfered ARO cells, growing in
vivo in absence of puromycine as selective antibiotic. Galectin-3
down-regulation in stable interfered ARO cells was checked in
western blot at different time points (12–72 hrs). After 4 days from
cell injection all the mice developed a visible subcutaneous tumor
with a median diameter size of 0.5 cm. The animals were then
injected in the tail vein with 100 mCi of
99mTc-labeled mAb to
galectin-3 (30 mg protein) and whole body images were acquired at
1 hr, 3 hrs, 6 hrs, 9 hrs and 24 hrs by using the high-resolution
gamma camera.
Images were analyzed drawing the regions of interest (ROI)
over the implanted tumor and over the counter lateral muscle
taken as background. As expected the optimal visualization of the
ARO-Gal-3
+ xenografts was obtained between 6 and 9 hours from
injection of the radiotracer, whereas galectin-3 negative tumors
were not detected at all (Fig. 1 panels A and B). Tumors were
finally explanted for histological evaluation and immuno-pheno-
typical analysis as shown in Figure 1.
In a different set of experiments, 20 ARO xenografted mice
were injected with 100 mCi of
99mTc-labeled mAb to galectin-3
(30 mg protein) and 5 groups of 4 animals each were sacrificed at
3 hrs, 6 hrs, 9 hrs, 12 hrs and 24 hrs post-injection, respectively.
Tissue samples from blood, liver, spleen, kidney, small bowel,
large bowel, muscle and ARO tumor xenografts were removed,
weighted and counted for the presence of radioactivity. All the
animals were imaged before killing with reproducible results (data
not shown). The in vivo bio-distribution of radio labeled galectin-3
mAb expressed as percentage of injected dose per gram of tissue
(%ID/g), showed a rapid blood clearance of the radiopharma-
ceutical within 3 hours from injection. Most of the radioactivity
was detected in the liver and kidneys indicating a prompt
clearance of the tracer via the hepatic and urinary tract (table 1).
As expected the tumor uptake of the galectin-3 specific
99mTc-
labelled mAb increased from 3 to 9 hrs post-injection. At 6 hrs
post-injection the target tumors were clearly visible while the
whole-body activity had essentially cleared (table 1 and fig. S2
online).
Although translation of these findings in the clinical setting will
require the use of humanized mAbs linked to different radionu-
clides and more extensive preclinical studies, we attempted to
simulate a galectin-3-based imaging of human thyroid cancer ex-
vivo. To this aim a fresh cervical lymph node surgically excised
from a patient bearing a papillary thyroid carcinoma metastasis
(histologically confirmed), was used as target for studying the
binding efficiency of the Gal-3 specific radiotracer.
Immediately after surgical removal the lymph node was cut in
half through the cancer lesion and was incubated at 37u C for
3 hrs in 50 ml saline solution containing 2 mCi of
99mTc-mAb to
Galectin-3 (0.1 mg protein) and 1% human serum albumin, in
Thyroid Cancer Imaging In Vivo
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mAb (displacement assay).
After extensive washing in saline solution a comparative
imaging of the two tissue preparations was performed. Results of
this experiment are shown in figure 2.
The mini-gamma camera promptly detected the thyroid cancer
metastasis (panel A), whereas a scanty tumor uptake of the
radiotracer was visible in the control, due to the displacement
effect of the cold mAb in excess (panel B).
Discussion
Altogether these results suggest the possibility to detect thyroid
cancer and other galectin-3 expressing tumors in vivo by using a
galectin-3 specific radio-immunoscintigraphy. The use of galectin-
3 radiotracer for detection of thyroid cancer in vivo is supported by
a solid molecular rationale [5,7–10]. Moreover we recently
demonstrated that galectin-3 immunotargeting represents an
useful diagnostic tool for identifying preoperatively malignant
thyroid proliferations on immuno-cytological bases, although some
thyroid carcinomas (about 10–15% depending by the studies) do
not express galectin-3 [10–14,17]. The galectin-3 based radio-
immunoscintigraphy proposed here, provides biological informa-
tion about thyroid nodules and represents an useful guide to
correctly identify those thyroid proliferations that should be
cytologically evaluated and/or promptly excised.
Combining galectin-3 imaging with thyroid FNA-cytology, in
fact, may allow to distinguishing preoperatively benign from
malignant thyroid proliferations with high efficiency. As a
consequence many unnecessary thyroidectomies could be avoided
and the clinical use of conventional thyroid scintigraphy with radio
iodide, which only provides functional information on specific
thyroid conditions, could be restricted to more selected clinical
questions. Further studies which use humanized galectin-3 specific
mAbs conjugated to different radionuclides will be necessary to
confirm and validate these findings. If the proposed diagnostic
approach will prove successful a targeted radio-ablation of
galectin-3 expressing tumors might also be explored by using






67Cu). A galectin-3 ‘radiation
targeted therapy’ delivers the radiation dose specifically to the
galectin-3 positive tumor with limited exposure of normal tissues.
Penetration of beta- rays in living tissues is of several millimeters
and the therapeutic effect may be obtained also in cancer cells that
do not take up directly the radiopharmaceutical (cross-fire effect).
This approach could be useful for both detection and treatment of
micro papillary thyroid carcinomas (lesions smaller than 1 cm,
commonly worded ‘occult PTC’), which are currently undetectable
preoperatively.
Furthermore, the possibility to treat primary and metastatic
thyroid malignancies that are galectin-3 positive but non-iodine
avid and for this reason they are not responsive to the conventional
radio-metabolic therapy with
131Iodine, represents an important
achievement in oncology that will be further investigated.
Preliminary data of in vivo imaging of galectin-3 positive
melanomas, lymphomas and breast carcinomas have been also
obtained opening interesting possibilities for the future to use radio
labeled mAbs to galectin-3 for in vivo imaging and treatment of
different types of human malignancies [27–31].
Supporting Information
Figure S1 Stability and labelling efficiency of the galectin-3
radiotracer. The stability of the radiotracer was evaluated by
incubating a sample of the radio labelled mAb in saline and serum
for 24 hours at 37uC. The percentage of technetium bound to the
mAb was assessed by Instant Thin Layer Chromatography- Silica
Gel based (ITLC-SG) strips at different time points. The graph
shows retention of technetium ranging between 100% and 85%
during the first six hours (around 360 minutes) with a slight
decrease from 6 to 24 hours (upper panel). The activity for
radiolabel mAb anti galectin-3 has been assessed in a titration
experiment. The best mAb/Tc ratio has been calculated by
varying the activity of 99mTc added to a stable volume of reduced
antibody. The labelling efficiency (LE) was evaluated by ITLC-
Table 1. Biodistribution ex vivo of
99mTc-labeled-mAb to
galectin 3 in mice xenografted with galectin-3 positive ARO
tumors.
Organ %ID/gm
3 hrs 6 hrs 9 hrs 12 hrs 24 hrs
Blood 0.16 0.09 0.07 0.04 0.03
Liver 0.51 0.29 0.35 0.27 0.12
Spleen 0.07 0.05 0.03 0.03 0.01
Kidney 0.19 0.17 0.19 0.17 0.08
Large intestine 0.03 0.04 0.05 0.07 0.04
Small intestine 0.03 0.02 0.02 0.02 0.01
Muscle 0.01 0.001 0.001 0.001 0.001
Tumor 0.05 0.07 0.10 0.05 0.03
Values are expressed as % of injected dose (ID) per gram of tissue.
Five groups of mice (four animals each) bearing galectin-3 positive ARO
xenografts were injected with 100 mCi of
99mTc-labeled mAb to galectin-3
(30 mg protein).
Data represent the average value of %ID/gm of tissue in 4 animals sacrificed at
3 hrs, 6 hrs, 9 hrs, 12 hrs and 24 hrs post-injection of the radiotracer.
doi:10.1371/journal.pone.0003768.t001
Figure 2. Ex-vivo binding of the
99mTc-labeled mAb to
Galectin-3 on papillary thyroid cancer metastasis in a lymph
node. The figure shows the lymph node specimen cut in half
longitudinally and imaged by using the mini gamma camera after
1 hr and 2 hrs of incubation with 2 mCi of
99mTc-labeled mAb to
Galectin-3 (0.1 mg protein) in saline solution, in presence (panel B) or
not (panel A) of an excess (100 mg) of unlabeled galectin-3 specific
mAb. Panel A shows tumour detection by radiotracer after 1 hr and
2 hrs of incubation. Panel B shows a consistent lower uptake of the
radiotracer in presence of an excess of unlabelled anti-gal3- mAb, due
to the specific displacement effect.
doi:10.1371/journal.pone.0003768.g002
Thyroid Cancer Imaging In Vivo
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corresponding to 30–40 mCi of activity and a labelling efficiency
up to 95%. An activity exceeding this value did not increase the
LE (lower panel B).
Found at: doi:10.1371/journal.pone.0003768.s001 (8.52 MB
DOC)
Figure S2 Tumor imaging in vivo by using 99mTc-labelled
mAb to Galectin-3 and a high-resolution portable mini gamma
camera. A) The high-resolution portable mini gamma camera
used in this study. B) Image captured by the high-resolution
gamma camera in a mouse bearing the galectin-3 positive thyroid
carcinoma xenograft ARO, after 6 hrs from i.v. injection of
100 mCi of 99mTc-labelled mAb to Galectin-3. The tumor
confirmed at histology was 1.2 cm in diameter and showed a
large central necrotic area corresponding to the lacuna that failed
to fix the radiotracer (arrow).
Found at: doi:10.1371/journal.pone.0003768.s002 (10.39 MB
DOC)
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